Cyclic GMP-AMP synthase (cGAS), an intracellular sensor of dsDNA, is a central driver of inflammatory diseases and an emerging therapeutic target, although optimization of cGAS inhibitors for the clinic is challenging because of the incomplete understanding of their mode of action. Here, the authors study the binding mode of G-chemotype human cGAS inhibitors, revealing key structural differences driving cGAS inhibitor cross-species potency shifts, and discover a novel cGAS inhibitor with exceptional mouse and human potency.
- Alexander M. Skeldon
- Li Wang
- Kelly A. Pike